163
Views
1
CrossRef citations to date
0
Altmetric
Articles

Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life

, , , , &
Pages 9-16 | Received 10 Jun 2020, Accepted 18 Nov 2020, Published online: 21 Dec 2020

References

  • Mottet N, van den Bergh RCN, Briers E, et al. EAU Guidelines: prostate cancer 2019. Eur Association of Urol;2019. Available from: https://uroweb.org/guideline/prostate-cancer/
  • Solberg A. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av prostatakreft. 6. utg. ed. Oslo: Helsedirektoratet;2015.
  • Vatne K, Stensvold A, Myklebust TA, et al. Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. Acta Oncol. 2017;56:1295–1301.
  • Kneebone A, Bergamin S. Salvage treatment for biochemical failure after radical prostatectomy: do we now have the answers? European Urology. 2020;77:699–700.
  • Adam M, Tennstedt P, Lanwehr D, et al. Functional outcomes and quality of life after radical prostatectomy only versus a combination of prostatectomy with radiation and hormonal therapy. Eur Urol. 2017;71:330–336.
  • Adam S, Koch-Gallenkamp L, Bertram H, et al. Health-related quality of life in long-term survivors with localised prostate cancer by therapy-results from a population-based study. Eur J Cancer Care (Engl). 2019;28:e13076.
  • Hu JC, Elkin EP, Krupski TL, et al. The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2006;107:281–288.
  • Moinpour CM, Hayden KA, Unger JM, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008;26:112–120.
  • van Stam MA, Aaronson NK, Pos FJ, et al. The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients. Eur Urol. 2016;70:751–757.
  • Suardi N, Gallina A, Lista G, et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol. 2014;65:546–551.
  • Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–2027.
  • Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329–2335.
  • Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–2930.
  • Steinsvik EA, Axcrona K, Dahl AA, et al. Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Int. 2012;109:1366–1374.
  • Storas AH, Sanda MG, Boronat OG, et al. Erectile dysfunction and sexual problems two to three years after prostatectomy among American, Norwegian, and Spanish patients. Clin Genitourin Cancer. 2016;14:e265–e273.
  • Fossa SD, Storas AH, Steinsvik EA, et al. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26). Scand J Urol. 2016;50:280–285.
  • Martin NE, Massey L, Stowell C, et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015;67:460–467.
  • Loyland B, Miaskowski C, Dahl E, et al. Psychological distress and quality of life in long-term social assistance recipients compared to the Norwegian population. Scand J Public Health. 2011;39:303–311.
  • Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1171–1178.
  • Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–144.
  • Donnelly DW, Donnelly C, Kearney T, et al. Urinary, bowel and sexual health in older men from Northern Ireland. BJU Int. 2018;122:845–857.
  • Fossa SD, Beyer B, Dahl AA, et al. Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique. Scand J Urol. 2019;53:385–391.
  • Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261.
  • Moltzahn F, Dal Pra A, Furrer M, et al. Urethral strictures after radiation therapy for prostate cancer. Investig Clin Urol. 2016;57:309–315.
  • Hofer MD, Gonzalez CM. Management of radiation-induced urethral strictures. Transl Androl Urol. 2015;4:66–71.
  • Skolarus TA, Dunn RL, Sanda MG, et al.; PROSTQA Consortium. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015;85:101–105.
  • Ring L, Hofer S, Heuston F, et al. Response shift masks the treatment impact on patient reported outcomes (PROs): the example of individual quality of life in edentulous patients. Health Qual Life Outcomes. 2005;3:55.
  • Delporte G, Henon F, Ploussard G, et al. Radical prostatectomy for locally advanced and high-risk prostate cancer: a systematic review of the literature. Prog Urol. 2018;28:875–889.
  • Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376:417–428.
  • Carrie C, Magne N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20:1740–1749.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.